Search results for "very"

showing 10 items of 6927 documents

Preventive and Therapeutic Role of Muscle Contraction Against Chronic Diseases.

2016

Background: Due to the continuing increase of the elderly population in the western countries, the prevalence of the main chronic diseases (obesity, type 2 diabetes and related metabolic disorders, arterial hypertension, vascular damage due to atherosclerotic process, cancer, chronic obstructive pulmonary disease, neurodegenerative diseases, chronic kidney disease, immune-mediated diseases) is increasing. There is incontrovertible evidence that regular physical activity contributes to the primary and secondary prevention of several chronic diseases and is associated with a reduced risk of premature death. Methods: In this review the most prevalent chronic pathologic conditions are discussed…

0301 basic medicinemedicine.medical_specialtyPopulationPsychological interventionType 2 diabetes01 natural sciences03 medical and health sciencesMetabolic DiseasesIntervention (counseling)NeoplasmsDrug DiscoverymedicineAnimalsHumansObesity0101 mathematicseducationIntensive care medicineExercisePhysical activity - Chronic diseasesPharmacologyeducation.field_of_studybusiness.industryCancermedicine.diseaseObesity010101 applied mathematics030104 developmental biologyDiabetes Mellitus Type 2Lifestyle changeChronic DiseasePhysical therapybusinessKidney diseaseMuscle ContractionCurrent pharmaceutical design
researchProduct

Hypoxie et régénération cardiaque : une nouvelle approche paradoxale de la cardioprotection

2017

IF 2.331; International audience

0301 basic medicinemedicine.medical_specialtyReactive oxygen species metabolismTranscription GeneticCardiac pathologyEnergy metabolismCardiac metabolismCardioprotectionHypoxie03 medical and health sciencesInternal medicinemedicineRégénérationAnimalsHumansRegenerationMyocytes CardiacTissue survivalHypoxiaCoeurCell ProliferationCardioprotectionHeart FailureTissue Survivalbusiness.industryOxygen metabolismHeartGeneral MedicineRecovery of FunctionHypoxia (medical)[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCell HypoxiaOxygenOxidative Stress030104 developmental biologyGene Expression RegulationAnesthesiaCardiologymedicine.symptomCardiology and Cardiovascular MedicinebusinessEnergy MetabolismReactive Oxygen SpeciesSignal TransductionArchives of cardiovascular diseases
researchProduct

Pathways of care for HIV infected children in Beira, Mozambique: pre-post intervention study to assess impact of task shifting

2018

Abstract Background In 2013, Mozambique implemented task-shifting (TS) from clinical officers to maternal and child nurses to improve care for HIV positive children < 5 years old. A retrospective, pre-post intervention study was designed to evaluate effectiveness of a new pathway of care in a sample of Beira District Local Health Facilities (LHFs), the primary, local, community healthcare services. Methods The study was conducted by accessing registries of At Risk Children Clinics (ARCCs) and HIV Health Services. Two time periods, pre- and post-intervention, were compared using a set of endpoints. Variables distribution was explored using descriptive statistics. T-student, Mann Whitney and …

0301 basic medicinemedicine.medical_specialtyReferralHIV InfectionsHIV infected childrenSettore MED/42 - Igiene Generale E ApplicataPost-intervention03 medical and health sciences0302 clinical medicineHIV exposed infants; HIV infected children; Human immunodeficiency virus; Paediatric HIV care and treatment; Pathways of care; Task-shiftingIntervention (counseling)EpidemiologyHealth caremedicineHumansHealth Workforce030212 general & internal medicineHuman immunodeficiency viruReferral and ConsultationMozambiqueRetrospective StudiesDescriptive statisticsbusiness.industryHuman immunodeficiency virusPublic healthlcsh:Public aspects of medicinePaediatric HIV care and treatmentPublic Health Environmental and Occupational HealthInfantHIV exposed infantlcsh:RA1-1270030112 virologyTask-shiftingHIV exposed infantsCD4 Lymphocyte CountChild PreschoolFamily medicineHealth Services ResearchBiostatisticsbusinessDelivery of Health CarePathways of careResearch ArticleBMC Public Health
researchProduct

Treatment challenges in and outside a network setting: Head and neck cancers.

2019

Head and neck cancer (HNC) is a rare disease that can affect different sites and is characterized by variable incidence and 5-year survival rates across Europe. Multiple factors need to be considered when choosing the most appropriate treatment for HNC patients, such as age, comorbidities, social issues, and especially whether to prefer surgery or radiation-based protocols. Given the complexity of this scenario, the creation of a highly specialized multidisciplinary team is recommended to guarantee the best oncological outcome and prevent or adequately treat any adverse effect. Data from literature suggest that the multidisciplinary team-based approach is beneficial for HNC patients and lea…

0301 basic medicinemedicine.medical_specialtySocio-culturaleSocial issuesMultidisciplinary team03 medical and health sciencesTherapeutic approach0302 clinical medicineRare DiseasesMultidisciplinary approachmedicineHumansAdverse effectIntensive care medicineHead and neck cancerReferral and ConsultationPatient Care TeamEuropean reference networks joint action of rare cancers ; Head and neck cancer ; Multidisciplinary team ; Rare diseasebusiness.industryHead and Neck NeoplasmHead and neck cancerEuropean reference networks joint action of rare cancersGeneral MedicineMultidisciplinary teammedicine.diseaseEurope030104 developmental biologyClinical researchOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisEuropean reference networks joint action of rare cancerSurgerybusinessEuropean reference networks joint action of rare cancers; Head and neck cancer; Multidisciplinary team; Rare disease; Surgery; OncologyRare diseaseDelivery of Health CareRare diseaseHumanEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society …

2021

International audience; Background and aimsThis European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients.MethodsEvidence-based review.ResultsStatin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-h…

0301 basic medicinemedicine.medical_specialtyStatinSettore MED/09 - Medicina InternaCombination therapymedicine.drug_classHigh-risk2019 ESC/EAS Dyslipidaemia GuidelineLipid goal030204 cardiovascular system & hematologyTriglyceride03 medical and health sciences0302 clinical medicineCombined treatmentcardiovascular diseaseInternal medicinemedicineHumanstriglycerides2019 ESC/EAS Dyslipidaemia Guidelines; combination treatment; LDL cholesterol; triglycerides; lipid goals; high-risk; cardiovascular diseaselipid goalsbusiness.industryTask forceAnticholesteremic AgentsPCSK9Cholesterol LDL[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismAtherosclerosis2019 ESC/EAS Dyslipidaemia Guidelines3. Good health030104 developmental biologyDiabetes Mellitus Type 2Combination treatmentAtherosclerosiLDL cholesterolEuropean atherosclerosis societyKexinlipids (amino acids peptides and proteins)Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessVery high risk
researchProduct

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure

2020

In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction. In our study, we investigated relationships between 5-FU clearance and markers of DPD activity such as uracilemia (U), dihydrouracilemia (UH2)/U ratio, or genotype of the gene encoding DPD (DPYD). All patients with gastrointestinal cancers who received 5-FU-based regimens form March 2018 to June 2020 were included in our study. They routinely benefited of a pre-therapeutic DPYD genotyping and phenotyping. During 5-FU infusion, blood samples were collected to measure 5-FU steady-state concentration in order to ada…

0301 basic medicinemedicine.medical_specialtyUH2/U ratioFOLFIRINOXtherapeutic drug monitoringuracilemiaPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441GastroenterologyArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineDrug DiscoveryDihydropyrimidine dehydrogenaseMedicine5-FUmedicine.diagnostic_testbusiness.industrylcsh:RDPDmedicine.diseasePrimary tumorGI cancer030104 developmental biologyDocetaxelTherapeutic drug monitoring030220 oncology & carcinogenesisToxicityUH<sub>2</sub>/U ratioMolecular MedicineDPYDbusinesspharmacokineticsmedicine.drugPharmaceuticals
researchProduct

Metabolismo lipídico y clasificación de las hiperlipemias

2021

This chapter summarises, and updates, lipid metabolism. Both pathways, exogenous metabolisms route via the chylomicrons, and the endogenous pathway of very low-density lipoproteins (VLDL) and low-density lipoproteins (LDL). The reverse cholesterol metabolism will also be mentioned. It also includes the current classification of hyperlipidaemias or hyperlipoproteinaemias, with a reminder of the phenotype classification, and further developments of the aetiological classification. Both parts have updated references, with which knowledge of this vast subject can be expanded.

0301 basic medicinemedicine.medical_specialtyVery low-density lipoproteinfood and beveragesEndogenyLipid metabolismArteriosclerosis030204 cardiovascular system & hematologyBiologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineEndocrinologyInternal medicinemedicinelipids (amino acids peptides and proteins)Pharmacology (medical)Cholesterol metabolismCardiology and Cardiovascular MedicineChylomicronClínica e Investigación en Arteriosclerosis
researchProduct

Beta-glucans and cancer: The influence of inflammation and gut peptide

2017

Dietary β-glucans are soluble fibers with potentially health-promoting effects. Gut peptides are important signals in the regulation of energy and glucose homeostasis. This article reviews the effects of different enriched β-glucan food consumption on immune responses, inflammation, gut hormone and cancer. Gut hormones are influenced by enriched β-glucan food consumption and levels of such peptide as YY, ghrelin, glucagon-like peptide 1 and 2 in humans influence serum glucose concentration as well as innate and adaptive immunity. Cancer cell development is also regulated by obesity and glucose dishomeostasy that are influenced by β-glucan food consumption that in turn regulated gut hormones.

0301 basic medicinemedicine.medical_specialtybeta-GlucansInflammationbeta-Glucan03 medical and health sciences0302 clinical medicineImmune systemGlucagon-Like Peptide 1Functional FoodNeoplasmsInternal medicineβ-GlucanDrug DiscoveryGlucagon-Like Peptide 2medicineAnimalsHumansInsulinGlucose homeostasisPeptide YYCancerInflammationPharmacologyPYYAnimalChemistryDrug Discovery3003 Pharmaceutical Sciencedigestive oral and skin physiologyOrganic ChemistryGeneral MedicineGlucagon-like peptide-2Glucagon-like peptide-1GhrelinGlucose030104 developmental biologyEndocrinology030220 oncology & carcinogenesisPeptide YYNeoplasmGhrelinmedicine.symptomGLP-1GLP-2HumanHormoneEuropean Journal of Medicinal Chemistry
researchProduct

Clinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine

2019

Abstract Background The identification of biomarkers to drive treatment is one of the most important objectives of precision medicine. During last years, the role of PIK3CA mutations have been related to clinical benefit deriving from treatment with PI3K, and mTOR inhibitors. In breast cancer (BC), PIK3CA mutations are widely present and the use, in clinical trials, of selective inhibitors improved clinical outcomes. The aim of this study is to assess the value of a monocentric genomic screening program to select patients for trials with experimental targeted agents. Methods We examined PIK3CA mutation in a cohort of 312 metastatic BC patients diagnosed at Hospital Clinico Valencia-INCLIVA …

0301 basic medicinemedicine.medical_specialtybusiness.industryHematologymedicine.diseaseDiscovery and development of mTOR inhibitorsPrecision medicineGenomic screeningClinical trialMutational analysis03 medical and health sciences030104 developmental biology0302 clinical medicineBreast cancerOncology030220 oncology & carcinogenesisInternal medicineCohortmedicinebusinessTriple negativeAnnals of Oncology
researchProduct

2019

PIK3CA-related overgrowth spectrum (PROS) encompasses a range of debilitating conditions defined by asymmetric overgrowth caused by mosaic activating PIK3CA variants. PIK3CA encodes the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K), a critical transducer of growth factor signaling. As mTOR mediates the growth-promoting actions of PI3K, we hypothesized that the mTOR inhibitor sirolimus would slow pathological overgrowth. Thirty-nine participants with PROS and progressive overgrowth were enrolled into open-label studies across three centers, and results were pooled. For the primary outcome, tissue volumes at affected and unaffected sites were measured by dual energy X-ray ab…

0301 basic medicinemedicine.medical_specialtybusiness.industrySirolimus therapyLow doseDiscovery and development of mTOR inhibitorsGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicinePrimary outcome030220 oncology & carcinogenesisSirolimusInternal medicinemedicineAsymmetric overgrowthbusinessAdverse effectPathologicalGenetics (clinical)medicine.drugGenetics in Medicine
researchProduct